PepGen is committed to transforming the treatment for people living with myotonic dystrophy type 1 (DM1) with our Enhanced Delivery Oligonucleotides (EDOs).
Oligonucleotides are genetic medicines that have the potential to modify the root cause of numerous neuromuscular disorders. They have been studied for multiple decades, however, by themselves, they do not enter into muscles easily and effectively.
PepGen has developed peptides that can be conjugated (connected) to oligonucleotides, to enhance and improve the delivery and activity of the oligonucleotides.
Preclinical and preliminary clinical data support further clinical development of PGN-EDODM1 in people living with DM1.
Learn more here
See our FAQ for additional resources and information.